Identification and Analysis of Circulating Biomarkers in Colorectal Cancer Treatment: Insights from Basic Data

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07235
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: Mitsukuni Suenaga 東京医科歯科大学, 大学院医歯学総合研究科, 准教授 (70462223)
• Co-Investigator(Kenkyū-buntansha): 馬島 哲夫 公益財団法人がん研究会, がん化学療法センター 分子生物治療研究部, 主任研究員 (30311228)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 効果予測マーカー

Outline of Final Research Achievements

In this study, candidate biomarkers obtained from basic research were validated in clinical samples. Using a cancer cell panel informatics approach, candidate biomarkers for regorafenib sensitivity were identified. An increase in the levels of soluble factor X of MMPs was observed in the sensitive colorectal cancer cell line, but significant changes were not observed in the resistant cell line. Already, data from clinical samples have confirmed that soluble factors X and Y of MMPs are involved in the effectiveness of regorafenib, and the results of analysis of both basic and clinical data were reported at an international conference in 2024. The possibility of combination therapy with regorafenib and antibodies against factor Y or FTD/TPI is also suggested.

Free Research Field

腫瘍内科

Academic Significance and Societal Importance of the Research Achievements

バイオマーカーの臨床応用にためには、本研究で行ったような信頼性の高い基礎データに基づいてバイオマーカーを検証するプロセスが不可欠である。臨床試験においても前向きな検証プロセスを通じて、有望なバイオマーカー候補の同定と臨床応用にむけたアプローチが必要である。